iTeos Therapeutics, Inc. (ITOS)
10.15
+0.02 (0.20%)
Inactive · Last trade price on Aug 28, 2025
iTeos Therapeutics Revenue
In the year 2024, iTeos Therapeutics had annual revenue of $35.00M with 177.89% growth.
Revenue (ttm)
$35.00M
Revenue Growth
+177.89%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
173
Market Cap
448.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.00M | 22.41M | 177.89% |
| Dec 31, 2023 | 12.60M | -255.04M | -95.29% |
| Dec 31, 2022 | 267.63M | -77.15M | -22.38% |
| Dec 31, 2021 | 344.78M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionITOS News
- 7 weeks ago - ITEOS THERAPEUTICS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - GlobeNewsWire
- 3 months ago - ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS - Business Wire
- 3 months ago - ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of iTeos Therapeutics, Inc. - PRNewsWire
- 3 months ago - iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right - GlobeNewsWire
- 4 months ago - iTeos Therapeutics Announces Its Intention to Wind Down Operations - GlobeNewsWire
- 5 months ago - iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients - GlobeNewsWire
- 6 months ago - iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 months ago - iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025 - GlobeNewsWire